For swing trading, we focus on short squeezes, biotech stocks, unusual options activity, and gappers. Get our swing trades emailed and/or texted to your cell phone. Membership Options.
For day trading, each morning pre-market, members are given the best long and short trades based on our proprietary news scanner. The scanner selects the most relevant news headlines and factors in where the stock is on the daily chart short term, intermediate term, and long term. The algorithm, based on years of trading experience, crunches the data and creates a list of the best trades for the day. You won't find a quality service like this anywhere, and we are sharing it with you on a free 7 day trial so you can see how good it is before joining.
Stocks Gapping Up 2018-03-05
CLSD Clearside Biomedical, Inc. (CLSD) 66.2; announced positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis.
XL XL Group Ltd (XL) 30.5; AXA announced today that it has entered into an agreement to acquire 100% of XL Group Ltd (XL), a leading global Property & Casualty commercial lines insurer and reinsurer with strong presence in North America, Europe, Lloyd's and Asia-Pacific. The merger agreement has been unanimously approved by the boards of AXA and XL Group. Total consideration for the acquisition would amount to USD 15.3 billion (or Euro 12.4 billion2), to be fully paid in cash. Under the terms of the transaction, XL Group shareholders will receive USD 57.60 per share3. This represents a premium of 33% to XL Group closing share price on March 2, 2018.
GTXI GTx, Inc. (GTXI) 24.9; announced additional results from a Phase 2 proof-of-concept clinical trial of 3 mg enobosarm administered orally in postmenopausal women with stress urinary incontinence (SUI), including magnetic resonance imaging (MRI) results from patients pelvic floor muscle. New data in a subset of women also suggests a positive treatment effect of enobosarm for urge incontinence (UI) suggesting a possible treatment effect for women with mixed incontinence. Results from a pre-specified analysis of MRI data demonstrate a statistically significant increase in pelvic floor muscle thickness and urethral muscle diameter after enobosarm treatment. Treatment with enobosarm also reduced mean UI episodes by approximately 68 percent in patients who experienced UI as well as SUI, based on a post hoc analysis of a subset of women with both UI and SUI.
CVRS Corindus Vascular Robotics, Inc. (CVRS) 17.1; announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for the CorPath GRX platform.
AIMT Aimmune Therapeutics, Inc. (AIMT) 6.1; announced that the results of its pivotal Phase 3 PALISADE trial of AR101 for the treatment of peanut allergy were presented today at the 2018 American Academy of Allergy, Asthma & ImmunologyWorld Allergy Organization Joint Congress in Orlando. Aimmune previously announced positive topline results of the PALISADE trial in February.
FNSR Finisar Corp. (FNSR) 2.3; to replace LendingTree in the S&P SmallCap 600
MOS Mosaic (MOS) 1.6; Cowen upgraded from Market Perform to Outperform with a price target of $32.00 (from $25.00).
Copyright dailystockplays.com All Rights Reserved